Every article on this site is written by AI from official sources and checked by a second AI. How it works
Proposed rule

Immunology and Microbiology Devices; Reclassification of Nucleic Acid-Based Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product; Proposed Amendment; Proposed Order; Request for Comments

Built by the Tribune's code from the Federal Register. No AI wrote this page. Published in the Federal Register Nov. 25, 2025. Document 2025-21071. Updated Nov. 17, 2026.

What it does

The Food and Drug Administration (FDA) is proposing to reclassify certain postamendments class III nucleic acid-based test systems indicated for use with a corresponding approved oncology therapeutic product (product codes OWD, PJG, PQP, and SFL) from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is also proposing a new device classification regulation, along with the special controls that FDA believes are necessary to provide a reasonable assurance of safety and effectiveness for these devices.

The Food and Drug Administration's summary, as published in the Federal Register.

What it would change

1 part of Title 21 of the Code of Federal Regulations:

21 CFR 866

What happens next and when

Submit electronic or written comments on the proposed order by January 26, 2026. Please see section X of this document for the proposed effective date when the new requirements apply and for the proposed effective date of a final order based on this proposed order.

The agency's dates, word for word.

Document number2025-21071
ActionProposed amendment; proposed order; request for comments.
AgenciesHealth and Human Services Department; Food and Drug Administration
PublishedNov. 25, 2025
Comments closeJan. 26, 2026
DocketFDA-2025-N-4622

Source: the Federal Register (public domain). The document in the Federal Register